GRAY - Graybug Vision reports full data from mid-stage wet AMD trial

Graybug Vision ([[GRAY]] -7.2%) has reported the results from full-data analysis of the Phase 2b ALTISSIMO trial of GB-102 for the treatment of wet age-related macular degeneration (wet AMD).Conducted across 33 sites in the U.S., the masked and controlled trial was designed to evaluate two doses of GB-102 with a single control arm of patients on aflibercept.The primary endpoint is the median time taken to the first supportive therapy with a vascular endothelial growth factor ((VEGF)) inhibitor.The mean change of best-corrected visual acuity ((BCVA)) and mean change of central subfield thickness ((CST)) of the retina were secondary endpoints which however were not powered to show the higher efficacy of GB-102 against aflibercept.During the 12-month treatment phase, GB-102 1mg was safe and well-tolerated, the company said adding that most treatment-related adverse events were mild to moderate.Compared with baseline, the control of CST in patients receiving twice-a-year GB-102 1mg was similar to bi-monthly aflibercept.

For further details see:

Graybug Vision reports full data from mid-stage wet AMD trial